EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Michelantonio De Fano iD, Line L Haurum, Christine R Schwarz, Francesca Porcellati, Andreas Andersen iD

Diabetes, Obesity and Metabolism · 2026-08 · 28 (8) · 6509-6532

DOI: 10.1111/dom.70888 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.05.2026. Verfasst von Michelantonio De Fano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Perugia University Medical School, Perugia, Italy. Hauptthemen laut MEDLINE: Gastric Inhibitory Polypeptide, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetic Nephropathies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist. Materials and Methods This narrative review synthesizes key physiological data of native GIP across tissues—especially the heart, vessels, kidney, and adipose tissue—and summarizes clinical evidence from the SUMMIT and the SURPASS programmes. Central to this review is the analysis of the SURPASS‐CVOT trial, which compared the cardiovascular protective effects of tirzepatide versus dulaglutide in individuals with type 2 diabetes and established atherosclerotic CV disease.

Results

Preclinical data regarding GIP receptor modulation in the cardiorenal district remains controversial, a contention partially reflected in recent clinical evidence. Within the innovative framework of SURPASS‐CVOT, tirzepatide established non‐inferiority to dulaglutide for 3‐point MACE while slowing eGFR decline in participants with high‐risk chronic kidney disease. Furthermore, the SUMMIT trial demonstrated that in individuals with obesity and heart failure (HF) with preserved ejection fraction, tirzepatide reduced the composite endpoint of CV death or worsening HF events, regardless of baseline kidney function. Despite these advancements, knowledge gaps persist regarding the potential synergistic cardiorenal benefits of combining dual incretin agonism with sodium‐glucose cotransporter‐2 inhibitors.

Conclusion

While adding GIP receptor agonism to GLP‐1 receptor agonism clearly improves cardiometabolic risk factors, its precise and independent contribution to long‐term CV and renal protection remains to be fully elucidated. Ongoing outcome trials, such as SURMOUNT‐MMO and TREASURE‐CKD, will provide additional insights into these effects. Furthermore, emerging strategies—including combining GIP receptor antagonism with GLP‐1 receptor agonism or moving toward triple agonism—represent promising alternatives to favorably modify the multiple determinants of cardiometabolic risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastric Inhibitory PolypeptideDiabetes Mellitus, Type 2Cardiovascular DiseasesDiabetic NephropathiesHumansTirzepatideReceptors, Gastrointestinal HormoneGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretinsGlucagon-Like PeptidesAnimalsKidneyImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Stichwörter der Autor:innen

GIPcardiovascular diseaseincretin therapyobesity therapytype 2 diabetes

Substanzen

Gastric Inhibitory PolypeptideTirzepatideReceptors, Gastrointestinal HormoneGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agentsgastric inhibitory polypeptide receptorIncretinsGlucagon-Like PeptidesdulaglutideImmunoglobulin Fc Fragments

Autor:innen und Institutionen

  • Department of Medicine and Surgery, Perugia University Medical School, Perugia, Italy.
  • Clinical and Translational Research, Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.

ORCID-Profile: Michelantonio De Fano, Andreas Andersen

Zitieren

APA

De Fano, M., Haurum, L. L., Schwarz, C. R., Porcellati, F., & Andersen, A. (2026). GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology. Diabetes, Obesity and Metabolism, 28(8), 6509-6532. https://doi.org/10.1111/dom.70888

Vancouver

De Fano M, Haurum LL, Schwarz CR, Porcellati F, Andersen A. GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology. Diabetes, Obesity and Metabolism. 2026;28(8):6509-6532. doi:10.1111/dom.70888

BibTeX
@article{DeFano2026,
  author = {De Fano, Michelantonio and Haurum, Line L and Schwarz, Christine R and Porcellati, Francesca and Andersen, Andreas},
  title = {GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {8},
  pages = {6509--6532},
  doi = {10.1111/dom.70888}
}
Kostenlos starten →